Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Dupilumab significantly reduces severe exacerbations and improves lung function in children with moderate-to-severe type 2 ...

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...

Upstream Bio's verekitug targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026 ...

The addition of dupilumab significantly reduced itching and hives compared with placebo in patients with chronic spontaneous urticaria (CSU) that was uncontrolled with H1-antihistamines ...